Skip to content

Outcomes After Albumin Vs Lactated Ringer's Solution in CABG and AVR Procedures

Outcomes After Albumin Vs Lactated Ringer's Solution in CABG and AVR Procedures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04652375
Enrollment
131
Registered
2020-12-03
Start date
2021-07-01
Completion date
2022-07-26
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Graft Surgery, Aortic Valve Replacement

Brief summary

This is a prospective, randomized, double-blinded study to compare the use of albumin versus lactated Ringer's solution in patients undergoing coronary artery bypass graft surgery and in patients undergoing aortic valve replacement surgery and evaluate the incidence of acute kidney injury as a primary outcome.

Detailed description

This will be a prospective, randomized, double-blinded study to compare the use of albumin versus lactated Ringer's solution in patients undergoing coronary artery bypass graft surgery and in patients undergoing aortic valve replacement surgery and evaluate the incidence of acute kidney injury as a primary outcome. Data will be collected from both EPIC and STS (society of thoracic surgeons) database. STS database extracts data from the electronic medical record and groups it in specific format to evaluate outcomes after cardiac surgery to compare institutional performance to similar institutions and the national average. Patients undergoing coronary artery bypass graft or aortic valve replacement will be randomized to receive either albumin or lactated Ringer's for fluid resuscitation post-surgery. The resuscitation volume will be based on clinical decision after examining all the hemodynamics parameters. This practice coincides with standard of care and current practice. All eligible patients will be randomly assigned to receive either albumin 5% or lactated Ringer's solution in a 1:1 ratio using computer-generated, permutated blocks of 2 - 4. Both solutions will be administered intravenously in 250 mL increments at the discretion of the physician until hemodynamic parameters are met. The IV infusion bag and IV tubing will be covered using opaque bags to allow for blinding.

Interventions

Participants will receive Albumin solution for fluid resuscitation post-surgery.

Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients greater than 18 years of age undergoing CABG and AVR procedures

Exclusion criteria

* Low ejection fraction (\<20%) End stage renal disease Chronic renal insufficiency Pre-operative Inotropic (eg. Dobutamine) or vasoactive IV infusions (e.g, norepinephrine) * Jehovah's Witness Emergent surgery (e.g, intra-aortic balloon pump) Pre-operative acute kidney injury based on AKIN criteria Non English speaking patients * Jehovah's Witness population will be excluded regardless of their preference with accepting Albumin because sometimes PRBC are used as part of ongoing resuscitation in bleeding patients and if patients cannot use blood, this will have a much bigger issue with resuscitation and this study is not designed to follow up that population.

Design outcomes

Primary

MeasureTime frameDescription
Acute Kidney InjuryWithin 72 hours post randomizationAcute kidney injury will be assessed by these criteria: Stage I. Increase 1.5-1.9 times from baseline or ≥ 0.3 mg/dl increase within 48 h. Urinary output (UOP) \< 0.5 ml/kg/h for 6-12 hours Stage II. Increase \> 2- to 3-fold from baseline. UOP \< 0.5 ml/kg/h for 12 hours Stage III. Increased \> 300% (\> 3-fold) from baseline, or ≥ 4.0 mg/dl with an acute increase of ≥ 0.5 mg/dl or on renal replacement therapy. UOP \< 0.3 ml/kg/h for 24 hours or anuria for 12 hours

Secondary

MeasureTime frameDescription
Extubation timeUp to 90 daysDuration of intubation
Length of stay in the ICUUp to 90 daysLength of stay in the ICU
Length of stay in the hospitalUp to 90 daysLength of stay in the hospital
Hospital readmissionReadmission within 30 days of dischargeAn episode when a patient who had been discharged from a hospital is admitted again within a specified time interval

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026